专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004073656A3 ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS 审中-公开
公开(公告)号：WO2004073656A3
公开(公告)日：2004-09-02
申请号：PCT/US2004/005247
申请日：2004-02-20
申请人： SEATTLE GENETICS, INC. , LAW, Che-Leung , WAHL, Alan, F. , SCHOLLER, Nathalie , PESTANO, Linda, A.
发明人： LAW, Che-Leung , WAHL, Alan, F. , SCHOLLER, Nathalie , PESTANO, Linda, A.
IPC分类号： A61K39/395
摘要： Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.

2. 发明申请

WO2004032828A2 ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS 审中-公开
标题翻译：抗CD20抗体药物治疗癌症和免疫缺陷病毒
公开(公告)号：WO2004032828A2
公开(公告)日：2004-04-22
申请号：PCT/US2003/023895
申请日：2003-07-30
申请人： SEATTLE GENETICS, INC. , WAHL, Alan, F. , SENTER, Peter, D. , LAW, Che-Leung , CERVENY, Charles, G.
发明人： WAHL, Alan, F. , SENTER, Peter, D. , LAW, Che-Leung , CERVENY, Charles, G.
IPC分类号： A61K
CPC分类号： A61K47/6851 , A61K47/6849
摘要： The present invention relates to methods and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides methods of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.
摘要翻译：本发明涉及用于治疗表达CD20的癌症和涉及CD20表达细胞的免疫疾病的方法和组合物。本发明的方法包括向受试者施用具有高效力和/或能够内化成CD20表达细胞的抗CD20抗体 - 药物偶联物。本发明还提供了包含这种缀合物的药物组合物和试剂盒。本发明还进一步提供了使用本发明的抗CD20抗体 - 药物共轭物的癌症和涉及CD20表达细胞的免疫疾病的组合疗法的方法和组合物。

3. 发明申请

WO2019108733A2 CD47 ANTIBODIES AND USES THEREOF FOR TREATING CANCER 审中-公开
公开(公告)号：WO2019108733A2
公开(公告)日：2019-06-06
申请号：PCT/US2018/062961
申请日：2018-11-29
申请人： SEATTLE GENETICS, INC.
发明人： GARDAI, Shyra , LEVENGOOD, Matthew , TRANG, Vivian , WESTENDORF, Lori , CAROSINO, Christopher , FELDHAUS, Michael , LAW, Che-Leung
IPC分类号： C07K16/28
摘要： Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

4. 发明申请

WO2004006753A2 SGA-72M, A CANCER ASSOCIATED ANTIGEN, AND USES THEREOF 审中-公开
标题翻译： SGA-72M，一种癌症相关抗原及其用途
公开(公告)号：WO2004006753A2
公开(公告)日：2004-01-22
申请号：PCT/US2003/022113
申请日：2003-07-11
申请人： SEATTLE GENETICS, INC. , PETROZIELLO, Joseph, M. , LAW, Che-Leung , WAHL, Alan, F.
发明人： PETROZIELLO, Joseph, M. , LAW, Che-Leung , WAHL, Alan, F.
IPC分类号： A61B
CPC分类号： G01N33/57415 , A01K2217/05 , A01K2217/075 , A61K2039/505 , C07K16/3015 , C12Q1/6837 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , G01N2500/04
摘要： The present invention relates to a gene and gene product, SGA-72M that is differentially expressed in cancer tissues and cell-lines. Suppression Subtractive Hybridization and microarray screening were used to screen for differential expression of SGA-72M in cancer tissues and cell-lines. Northern blot analysis and semi-quantitative RTPCR demonstrated over expression of SGA-72M in breast cancer tissue and breast cancer derived cell-lines. The gene is expressed as a 4.2kb mRNA. The SGA-72M cDNA comprises an open reading frame encoding 1342 amino acids. Monitoring expression levels of SGA-72M is useful for the diagnosis and prognosis of cancer as well as for evaluating the risk of developing certain types of cancers and the risk of metastasis of cancer. Antagonists that inhibit SGA-72M expression or activity are useful for the treatment of cancer. The SGA-72M polypeptide is associated with the plasma membrane and is on the cell surface of breast carcinoma cells and is a useful target for antibody-based therapeutics.
摘要翻译：本发明涉及在癌组织和细胞系中差异表达的基因和基因产物SGA-72M。使用抑制消减杂交和微阵列筛选筛选SGA-72M在癌组织和细胞系中的差异表达。 RNA印迹分析和半定量RTPCR证实在乳腺癌组织和乳腺癌来源的细胞系中SGA-72M的过表达。该基因表达为4.2kb mRNA。 SGA-72M cDNA包含编码1342个氨基酸的开放阅读框。监测SGA-72M的表达水平对于癌症的诊断和预后以及评估发展某些类型癌症的风险和癌症转移的风险是有用的。抑制SGA-72M表达或活性的拮抗剂可用于治疗癌症。 SGA-72M多肽与质膜相关并且在乳腺癌细胞的细胞表面上，并且是基于抗体的治疗剂的有用靶标。

5. 发明申请

WO2019108733A3 CD47 ANTIBODIES AND USES THEREOF FOR TREATING CANCER 审中-公开
公开(公告)号：WO2019108733A3
公开(公告)日：2019-06-06
申请号：PCT/US2018/062961
申请日：2018-11-29
申请人： SEATTLE GENETICS, INC.
发明人： GARDAI, Shyra , LEVENGOOD, Matthew , TRANG, Vivian , WESTENDORF, Lori , CAROSINO, Christopher , FELDHAUS, Michael , LAW, Che-Leung
IPC分类号： C07K16/28 , A61P35/00
摘要： Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

6. 发明申请

WO2012054748A3 SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY 审中-公开
公开(公告)号：WO2012054748A3
公开(公告)日：2012-04-26
申请号：PCT/US2011/057130
申请日：2011-10-20
申请人： SEATTLE GENETICS, INC. , LEWIS, Timothy S. , LAW, Che-Leung , MCEARCHERN, Julie A.
发明人： LEWIS, Timothy S. , LAW, Che-Leung , MCEARCHERN, Julie A.
IPC分类号： A61K39/00
摘要： The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.

7. 发明申请

WO2006044643A2 ANTI-CD70 ANTIBODY AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER AND IMMUNE DISORDERS 审中-公开
标题翻译：抗CD70抗体及其在治疗和预防癌症和免疫疾病中的用途
公开(公告)号：WO2006044643A2
公开(公告)日：2006-04-27
申请号：PCT/US2005/036994
申请日：2005-10-14
申请人： SEATTLE GENETICS, INC. , LAW, Che-Leung , MCEARCHERN, Julie , WAHL, Alan, F.
发明人： LAW, Che-Leung , MCEARCHERN, Julie , WAHL, Alan, F.
IPC分类号： A61K39/395
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/732 , C07K2317/734
摘要： Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, systatic or immunosuppressive without conjugation to a therapeutic agenst, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
摘要翻译：公开了诱导细胞毒性，系统性或免疫抑制性而不与治疗性抗原偶联的CD70结合剂，如抗-CD70抗体和衍生物，以及包含抗体或衍生物的药物组合物和试剂盒。还公开了用于治疗和预防表达CD70的癌症和免疫学病症的方法，其包括向受试者施用CD70结合剂。

8. 发明申请

WO2017096274A1 CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT INHIBITOR 审中-公开
标题翻译：使用2-脱氧-2-氟-L-核糖与检验点抑制剂联合治疗癌症
公开(公告)号：WO2017096274A1
公开(公告)日：2017-06-08
申请号：PCT/US2016/064783
申请日：2016-12-02
申请人： SEATTLE GENETICS, INC.
发明人： GARDAI, Shyra , LAW, Che-Leung , SENTER, Peter , OKELEY, Nicole , FIELD, Jessica
IPC分类号： A61K31/7024 , A61K31/7042 , A61K31/70 , A61K31/02 , A61K39/395 , C07K16/28 , C07K16/32
CPC分类号： A61K31/70 , A61K39/39541 , A61K45/06 , C07K16/2818 , A61K2300/00
摘要： The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an effective amount of 2-deoxy-2-fluoro-L-fucose or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination with a checkpoint inhibitor.
摘要翻译：本发明涉及治疗癌症的方法，其包括向有需要的受试者施用有效量的2-脱氧-2-氟-L-岩藻糖或其前药或药学上可接受的盐与检查点抑制剂组合。

9. 发明申请

WO2016069919A1 DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES 审中-公开
标题翻译：非结合抗CD40抗体的剂量和给药
公开(公告)号：WO2016069919A1
公开(公告)日：2016-05-06
申请号：PCT/US2015/058108
申请日：2015-10-29
申请人： SEATTLE GENETICS, INC.
发明人： GARDAI, Shyra , LAW, Che-Leung , PENG, Stanford , YANG, Jing , NEFF-LAFORD, Haley
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04
CPC分类号： A61K39/3955 , A61K39/395 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61M25/0012 , A61M25/0017 , A61M25/002 , A61M25/0068 , C07K16/2878 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2317/92
摘要： This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
摘要翻译：本发明涉及使用非岩藻糖化抗CD40抗体治疗癌症和慢性感染性疾病的方法。

10. 发明申请

WO2004024869A2 CANCER ASSOCIATED ANTIGENS, SGA-56M AND SGA-56MV, AND USES THEREOF 审中-公开
标题翻译：癌症相关抗原，SGA-56M和SGA-56MV及其用途
公开(公告)号：WO2004024869A2
公开(公告)日：2004-03-25
申请号：PCT/US2003/028676
申请日：2003-09-12
申请人： SEATTLE GENETICS, INC. , PETROZIELLO, Joseph, P. , LAW, Che-Leung , YAMANE, Andrew, K. , WAHL, Alan, F.
发明人： PETROZIELLO, Joseph, P. , LAW, Che-Leung , YAMANE, Andrew, K. , WAHL, Alan, F.
IPC分类号： C12N
CPC分类号： G01N33/57415 , C07K14/4748
摘要： The present invention relates to nucleic and amino acid sequences of SGA-56M and variants thereof. An exemplary variant of SGA-56M is SGA-56Mv. SGA-56M and SGA-56Mv are differentially expressed in cancer tissues and transformed cell lines. In particular, these genes are expressed at elevated levels in breast cancer and lung cancer tissues and cell lines. The present invention is also directed to methods for diagnosing a cancer in a subject, determining the prognosis of a cancer patient, and/or monitoring the efficacy of a treatment regimen for a cancer patient. The present invention further provides methods for screening and identifying modulators (e.g., antagonists or agonists) of SGA-56M and/or SGA-56Mv expression and/or activity. Antagonists identified using the methods of the invention are useful for the treatment of cancer patients. Also encompassed by the present invention are compositions including nucleic and/or amino acid sequences of SGA-56M and SGA-56Mv or SGA-56M/SGA-56Mv modulators and a pharmaceutically acceptable carrier. Such compositions may be used to advantage to treat a subject with a cancer to ameliorate the symptoms of the cancer or reduce the cancer cell burden in the subject. These compositions may also be utilized to prevent or delay the onset of a cancer in a subject exhibiting a predisposition to developing a cancer.
摘要翻译：本发明涉及SGA-56M的核酸和氨基酸序列及其变体。 SGA-56M的示例性变体是SGA-56Mv。 SGA-56M和SGA-56Mv在癌组织和转化细胞系中差异表达。特别地，这些基因在乳腺癌和肺癌组织和细胞系中以升高的水平表达。本发明还涉及用于诊断受试者中的癌症的方法，确定癌症患者的预后和/或监测癌症患者的治疗方案的功效。本发明还提供筛选和鉴定SGA-56M和/或SGA-56Mv表达和/或活性的调节剂（例如拮抗剂或激动剂）的方法。使用本发明方法鉴定的拮抗剂可用于治疗癌症患者。本发明还包括包含SGA-56M和SGA-56Mv或SGA-56M / SGA-56Mv调节剂的核酸和/或氨基酸序列和药学上可接受的载体的组合物。这样的组合物可用于治疗患有癌症的受试者以改善癌症的症状或降低受试者的癌细胞负担。也可以利用这些组合物来预防或延迟患有发展为癌症倾向的受试者的癌症的发作。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式